We searched PubMed and MEDLINE for articles that were published between Jan 1, 2007, and June 30, 2020, using the search terms “CAR-T cell therapy”, “CAR”, “chimeric antigen receptor”, “cellular immunotherapy”, “immune reconstitution”, “complications”, “adverse events”, “side effects”, “infection”, “reactivation”, and “infectious complications.” Articles resulting from these searches, and relevant references cited in those articles, were reviewed. Only articles published in English were
ReviewChimeric antigen receptor T-cell therapy for the treatment of lymphoid malignancies: is there an excess risk for infection?
Introduction
Cellular immunotherapy using T cells genetically engineered to express a chimeric antigen receptor (CAR) has rapidly emerged as a promising new treatment for a broad range of cancers, particularly lymphoid malignancies. Now, a new generation of CAR T cells with improved efficacy and safety has been designed.1, 2 The impressive results obtained in patients with CD19+ B-cell malignancies treated with second-generation anti-CD19 CAR T cells led to US Food and Drug Administration approval of two of these therapies: tisagenlecleucel for the treatment of young adults with relapsed or refractory B-cell acute lymphocytic leukaemia, and tisagenlecleucel or axicabtagene ciloleucel for the treatment of adults with some types of relapsed or refractory large B-cell lymphoma.3, 4, 5 Approval for a third product, lisocabtagene maraleucel (also known as liso-cel or JCAR017), is expected during 2020.2 Anti-CD19 CAR T-cell therapy, has also shown high overall response rates in patients with other B-cell non-Hodgkin lymphomas.2, 6 Products targeting antigens other than CD19 are being investigated in patients with other haematological malignancies or solid tumours.7
Patients receiving CAR T-cell therapy might be at an increased risk for infection because of several factors,8 including the cumulative immunosuppression associated with the underlying malignant disease and its previous treatment, and the cytotoxic and lymphodepleting chemotherapy administered before cell infusion.9 In addition, CAR T-cell infusion depletes normal CD19+ B cells, potentially resulting in protracted hypogammaglobulinaemia.10 Finally, preliminary data show that CAR T-cell therapy might directly cause protracted cytopenia via a chemokine-mediated mechanism.
Importantly, the two most frequent and feared treatment-related toxic effects of CAR T-cell therapy, cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS), are associated with substantial immunosuppression. CRS is usually low grade, with reported incidences ranging from 43% to 65%,3, 4, 5 and can be safely managed with supportive care and, rarely, tocilizumab (an anti-interleukin [IL]-6 monoclonal antibody approved for rheumatoid arthritis treatment). However, ICANS is commonly high grade (in 35–65% of cases)3, 4, 5 and only treatable with corticosteroids. Accordingly, the current management of CAR T-cell therapy-associated toxicity also increases the risk of infection.9, 10, 11 The figure depicts the most common CAR T-cell therapy-associated immunosuppression and infection risk factors.
In this Review, we offer perspectives on the infectious complications of anti-CD19 CAR T-cell therapy for the treatment of lymphoid malignancies. Specifically, we provide an overview of the infection risks related to the lymphodepleting conditioning regimens used in these patients, the type and status of the underlying malignancy, and the potential immunosuppressive effect from the treatment of CAR T-cell therapy toxicities. We seek to discuss this complex area in the contest of available recommendations regarding anti-infective prophylaxis in these patients (published by the European Society for Blood and Marrow Transplantation [EBMT] and the Joint Accreditation Committee of the International Society for Cell and Gene Therapy).12 Our goal is to provide a conceptual framework for developing future prediction models to stratify by risk patients with lymphoid malignancies treated with CAR T-cell therapy, to improve infection management in this challenging group of patients.
Section snippets
Infectious complications of CAR T-cell therapy
Studies of the infectious complications related to CAR T-cell therapy are scarce and difficult to interpret because of their retrospective single-centre design and differences in patients' characteristics, CAR T-cell therapy doses and administration schedules, antimicrobial prophylaxis use, and diagnostic approaches (table 1 and table 2).13, 14, 15, 16, 17, 18, 19
The largest case series consisted of 133 adult patients with relapsed or refractory CD19+ acute lymphocytic leukaemia, chronic
Risk factors associated with infectious complications of CAR T-cell therapy
Some of the reported risk factors associated with infection are related to the host's immune system before CAR T-cell therapy. Other factors are directly associated with the use of lymphodepleting chemotherapy either before cell infusion or with the infusion of cells (panel 1).
Differentiating infection from CAR T-cell therapy toxicity
Fever, malaise, anorexia, and myalgia are features of CRS and, in severe cases, CRS can mimic a sepsis-like syndrome with hypotension, hypoxia, and multiorgan dysfunction. Also, CAR T-cell therapy-associated ICANS can mimic infectious encephalitis, interfering in the management of this complication. Beyond sepsis-like and encephalitis-like syndromes, CAR T-cell therapy-associated CRS rarely mimics infections in other organs, posing a great diagnostic dilemma.9, 10, 62, 63, 64, 65 Thus, it is
Future perspectives
Several clinical research questions regarding CAR T-cell therapy and infections remain (panel 3). For example, with the development of new generations of CAR T cells, researchers will need to determine whether these new CAR products are associated with a reduced or greater risk of infection than earlier products. CAR T cells can be engineered with safety switches to turn off immunotherapy, which include suicide genes, combinatorial target-antigen recognition, synthetic Notch receptors,
Search strategy and selection criteria
References (74)
- et al.
CAR T cells: continuation in a revolution of immunotherapy
Lancet Oncol
(2020) - et al.
Toxicities of chimeric antigen receptor T cells: recognition and management
Blood
(2016) - et al.
Infectious complications of CD19-targeted chimeric antigen receptor-modified T-cell immunotherapy
Blood
(2018) - et al.
Late events after treatment with CD19-targeted chimeric antigen receptor modified T cells
Biol Blood Marrow Transplant
(2020) - et al.
Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial
Lancet
(2010) - et al.
Incidence and outcome of invasive fungal diseases after allogeneic stem cell transplantation: a prospective study of the Gruppo Italiano Trapianto Midollo Osseo (GITMO)
Biol Blood Marrow Transplant
(2014) - et al.
How I prevent infections in patients receiving CD19-targeted chimeric antigen receptor T cells for B-cell malignancies
Blood
(2020) - et al.
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial
Lancet Oncol
(2019) - et al.
Safety of CAR T-cell therapy in patients with B-cell lymphoma and chronic hepatitis B or C virus infection
Blood
(2019) - et al.
Severe early hepatitis B reactivation in a patient receiving anti-CD19 and anti-CD22 CAR T cells for the treatment of diffuse large B-cell lymphoma
J Immunother Cancer
(2019)
Impact of bridging chemotherapy on clinical outcomes of CD19 CAR T therapy in relapse/refractory diffuse large B- cell lymphoma in real world experience
Blood
Radiation therapy as a bridging strategy for CAR T cell therapy with axicabtagene ciloleucel in diffuse large B-cell lymphoma
Int J Radiat Oncol Biol Phys
Radiation therapy can be an effective bridging strategy prior to axicabtagene ciloleucel therapy for relapsed/refractory large B-cell lymphoma
Blood
Long-duration complete remissions of diffuse large B cell lymphoma after anti-CD19 chimeric antigen receptor T cell therapy
Mol Ther
Persistence of long-lived plasma cells and humoral immunity in individuals responding to CD19-directed CAR T-cell therapy
Blood
Durable preservation of antiviral antibodies after CD19-directed chimeric antigen receptor T-cell immunotherapy
Blood Adv
Practice parameter for the diagnosis and management of primary immunodeficiency
J Allergy Clin Immunol
CAR-T - and a side order of IgG, to go?—Immunoglobulin replacement in patients receiving CAR-T cell therapy
Blood Rev
ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells
Biol Blood Marrow Transplant
CD19 CAR-T therapy and sepsis: dancing with the devil
Blood
Increased cortical glycolysis following CD19 CART therapy: a radiographic surrogate for an altered blood-brain barrier
Blood
Immune effector cell-associated neurotoxicity syndrome (ICANS) after CD19-directed chimeric antigen receptor T-cell therapy (CAR-T) for large B-cell lymphoma: predictive biomarkers and clinical outcomes
Blood
Infection risk and safety of corticosteroid use
Rheum Dis Clin North Am
Glucocorticoids and invasive fungal infections
Lancet
Tocilizumab not associated with increased infection risk after CAR T-cell therapy: implications for COVID-19?
Blood
Acute kidney injury and electrolyte abnormalities after chimeric antigen receptor T-cell (CAR-T) therapy for diffuse large B-cell lymphoma
Am J Kidney Dis
Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy
Blood
Checkpoint inhibition and infectious diseases: a good thing?
Trends Mol Med
Chimeric antigen receptor T-cell therapy during the COVID-19 pandemic
Biol Blood Marrow Transplant
CAR T-cell therapy for B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia: clinical trials and real-world experiences
Front Oncol
Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia
N Engl J Med
Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma
N Engl J Med
Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma
N Engl J Med
Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia
Sci Transl Med
CAR T cell immunotherapy for human cancer
Science
Infections associated with the new ‘nibs and mabs’ and cellular therapies
Curr Opin Infect Dis
Early and late hematologic toxicity following CD19 CAR-T cells
Bone Marrow Transplant
Cited by (43)
ANTIFON-CLIC®, a new clinical decision support system for the treatment of invasive aspergillosis: is it clinically relevant?
2023, Annales Pharmaceutiques FrancaisesProcess and General Management of Patients Undergoing Chimeric Antigen Receptor Therapies
2023, Manual of Hematopoietic Cell Transplantation and Cellular TherapiesMiscellaneous Complications of Chimeric Antigen Receptor T-Cell Therapy
2023, Manual of Hematopoietic Cell Transplantation and Cellular TherapiesInfectious complications of chimeric antigen receptor (CAR) T-cell therapies
2023, Seminars in HematologyManagement of secondary immunodeficiency in hematological malignancies in the era of modern oncology
2023, Critical Reviews in Oncology/HematologyCitation Excerpt :However, understanding the infection risk of CAR-T therapy is complicated due to the multi-faceted nature of the immunosuppression involved. Infection risk may be heightened due to the immunosuppressive conditioning regimens prior to CAR-T therapy, the CAR-T product itself, and the potential adverse events of CAR-T therapy (cytokine release syndrome [CRS] and immune effector cell-associated neurotoxicity syndrome [ICANS]), which may increase infection risk but also require management with corticosteroids, further heightening potential infection risk (Gudiol et al., 2021). Hypogammaglobulinemia resulting from B-cell aplasia may be a common adverse event of CAR-T therapy, though this remains poorly understood, as reported rates vary due to the heterogeneity of study methods and definitions (Hill et al., 2019).